BioSpace News Archive

DolCas Biotech, Ltd. has added to its formidable portfolio of better-for-you botanicals a new, highly concentrated all-natural ginger root extract, branded as Ginfort™.

H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS). The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in

Strong execution in Medical and Dental drives record financial results - Demand for infection prevention products continues to accelerate - Strong recurring revenue mix and cost discipline driving increased profitability - Hu-Friedy synergies well ahead of schedule - Net sales of $297.0M, up 15.5% - GAAP diluted EPS of $0.57, up 307.1% - Non-GAAP diluted EPS of $0.90, up 38.5% - GAAP net income of $24.5M, up 324.2%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development. Dr. Kieffer brings over 20 years of virologic research and pharmaceutical industry experience to Enanta, with proven expertise in drug

Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market

Bristol Myers Squibb (NYSE: BMY) and Scripps Research today announced that Bristol Myers Squibb has endowed a chair in chemistry at Scripps Research to advance scientific research critical to drug discovery. Scripps Research has named Professor Jin-Quan Yu, PhD , a pioneering chemist whose research has paved the way to powerful new techniques used in fields ranging from drug discovery to mat

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it has been awarded a research grant expected to total $15 million over 3 years from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support its ACT-AD Phase 2 clinical trial for ATH-1017, Athira’s lead therapeutic candida

- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo - controlled single and multiple ascending dose clinical trials in Q2 2021

Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the closing of its previously announced underwritten public offering of 7,645,259 shares of its common stock at a public offering price of $3.27 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other off

Rapidly growing biopharma selects ArisGlobal’s LifeSphere® MultiVigilance 10, benefits from industry’s first cognitive automation and AI-enabled safety system, a game-changer for patient safety